Psilocybin for the Aging Brain — UC Berkeley's PLASTICITY Study

The Study (In Plain English)

UC Berkeley's Center for the Science of Psychedelics just launched the PLASTICITY study — the first neuroimaging research to test psilocybin specifically in healthy older adults, ages 60 to 85.

This isn't about depression. It isn't about PTSD. It's about something more fundamental: can psilocybin reverse the neuroplasticity decline that comes with aging?

Why This Study Is Different

Almost every psychedelic study to date has focused on psychiatric conditions in younger or middle-aged adults. The question has always been: "Can this compound treat a disorder?"

PLASTICITY asks a different question: "Can this compound restore a capacity?"

Neuroplasticity — the brain's ability to form new connections, reorganize existing ones, and adapt to new information — declines steadily after age 30. By 60, the brain is significantly less flexible than it was at 25. This isn't a disease. It's the normal trajectory of aging.

But "normal" doesn't mean "irreversible."

What They're Measuring

The study uses functional MRI (fMRI) before, during, and after psilocybin administration to track:

Neural connectivity changes — How much do brain regions that have grown isolated over decades start communicating again?

Emotional regulation — Aging brains tend toward rigid emotional patterns. Fear becomes more fixed. Joy becomes less spontaneous. Can psilocybin reopen emotional range?

Social connectivity — Isolation is one of the strongest predictors of cognitive decline and mortality in older adults. The study measures whether psilocybin experiences lead to measurable changes in social engagement and sense of connection.

The Neuroplasticity Window

The most provocative hypothesis behind PLASTICITY is what researchers call the "neuroplasticity window."

Animal studies have shown that psilocybin promotes rapid dendritic growth — the physical sprouting of new connections between neurons. This effect peaks within 24 hours and remains detectable for weeks. In younger brains, this is interesting. In older brains with decades of pruned connections, it could be transformative.

The question is whether the aging human brain responds the same way the aging rodent brain does. That's what fMRI will reveal.

Why 60 to 85?

This age range was deliberately chosen to span early aging (60s, typically mild cognitive changes) through late aging (80s, significant structural brain changes). If psilocybin shows neuroplasticity effects across this range, it suggests the mechanism is robust enough to work even in substantially aged brains.

If the effect only appears in the 60s cohort, that tells researchers there may be a "window of intervention" — a period when the aging brain is still responsive.

Either result is valuable.

The Implications

If PLASTICITY shows what the researchers hope — that a single psilocybin dose can measurably increase neuroplasticity in older adults — the implications extend far beyond psychedelic therapy:

• Cognitive maintenance: Not treating Alzheimer's, but potentially delaying the decline that precedes it
• Emotional vitality: Restoring the emotional flexibility that erodes with age
• Social reconnection: Addressing the isolation that accelerates cognitive and physical decline in older adults
• Combination approaches: Psilocybin-enhanced neuroplasticity combined with cognitive training, physical exercise, or social engagement programs

The Cautions

This is a study launch, not a result. No data has been published yet. The history of neuroscience is littered with promising hypotheses that didn't survive controlled testing.

Psilocybin also carries real risks for older adults: cardiovascular effects, psychological distress, and potential interactions with the medications that are common in this age group. The study has extensive screening and safety protocols for this reason.

The Bottom Line

We spend billions trying to treat the diseases of aging. We spend almost nothing trying to maintain the brain's fundamental capacity to adapt.

PLASTICITY is testing whether a single psilocybin dose can do what no pharmaceutical has achieved: not treat a disease, but restore a capability. The brain's ability to grow, change, and connect — the thing we lose so gradually we barely notice until it's gone.

Results are expected in late 2026 or early 2027.